Le Wang
52Patents
14h-index
103Co-inventors
87Inventor score
Filing activity: Mar 31, 1993 → Oct 7, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8563735B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 70 | Active |
| US8546399B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 57 | Active |
| US8586754B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 55 | Active |
| US6201001A | Imidazole antiproliferative agents | Human Necessities | 49 | Expired |
| US8557983B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 40 | Active |
| US8580794B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 35 | Active |
| US8232273B2 | Heterocyclic compounds and methods of use | Chemistry; Metallurgy | 26 | Active |
| US8952157B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 19 | Active |
| US6228868A | Oxazoline antiproliferative agents | Chemistry; Metallurgy | 19 | Expired |
| US6310095A | Inhibitors of protein isoprenyl transferases | Chemistry; Metallurgy | 17 | Expired |
| US9034875B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US9029404B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 16 | Active |
| US9174982B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 15 | Active |
| US6221865A | Inhibitors of protein isoprenyl transferases | Chemistry; Metallurgy | 14 | Expired |
| US6204293A | Inhibitors of protein isoprenyl transferases | Chemistry; Metallurgy | 10 | Expired |
| US9072748B2 | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US9045420B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US8980879B2 | Bromodomain inhibitors | Emerging Cross-Sectional Technologies | 9 | Active |
| US9073855B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 9 | Active |
| US9303025B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Emerging Cross-Sectional Technologies | 9 | Active |
| US9125913B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | Chemistry; Metallurgy | 8 | Active |
| US8940737B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | Chemistry; Metallurgy | 7 | Active |
| US8148384B2 | Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeutics | Human Necessities | 6 | Active |
| US8445679B2 | 7-substituted indole MCL-1 inhibitors | Chemistry; Metallurgy | 6 | Active |
| US7956185B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | Chemistry; Metallurgy | 5 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.